Loading
Furosemide - LOW-dose Natriuresis-Guided Strategy / Acute Heart Failure (AHF) / Furosemide - HIGH-dose Natriuresis-Guided Strategy · Interventional Study
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed interventional trial comparing high-dose and low-dose natriuresis-guided diuretic strategies against standard care in 109 patients with acute heart failure. The registry record confirms recruitment completion but reports no outcome results; the primary endpoints—24-hour urinary sodium excretion, urine volume, and breathlessness change—remain unpublished.
Interventional, Randomized, Parallel, Open label, Treatment purpose. Acute Heart Failure (AHF); age from 18 Years. Intervention: HIGH-dose Natriuresis-Guided Therapy; LOW-dose Natriuresis-Guided Therapy. Compared with: Standard of Care — Active Comparator. n = 109. 1 site: Malaysia.
This is a completed interventional trial comparing high-dose and low-dose natriuresis-guided diuretic strategies against standard care in 109 patients with acute heart failure. The registry record confirms recruitment completion but reports no outcome results; the primary endpoints—24-hour urinary sodium excretion, urine volume, and breathlessness change—remain unpublished.
Results are not posted in this registry record; no efficacy, safety, or clinical outcome data are reported.
Results are not yet available from this registry record. Once published, the study may inform optimal diuretic dosing and natriuresis-guided protocols in acute heart failure management.
Registry record of a completed interventional trial in acute heart failure with 109 participants, but no results posted; early-phase design testing natriuresis-guided decongestion at different diuretic intensities.
As stated by the source record.
Quoted from the source exactly as published.
Results are not yet available from this registry record. Once published, the study may inform optimal diuretic dosing and natriuresis-guided protocols in acute heart failure management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07804654). This is a study registration, not published results. Lead sponsor: Universiti Teknologi Mara. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 109 participants (ACTUAL). Conditions: Acute Heart Failure (AHF). Interventions: DRUG: Furosemide - HIGH-dose Natriuresis-Guided Strategy; DRUG: Furosemide - LOW-dose Natriuresis-Guided Strategy; DRUG: Loop Diuretic - Standard of Care. Primary outcome measures: 24-Hour Urinary Sodium Excretion , From randomisation to 24 hours; 24-Hour Urine Volume , From randomisation to 24 hours; Change From Baseline in Breathlessness Likert Score at 24 Hours , Baseline and 24 hours after randomisation. Brief summary: The goal of this clinical trial is to learn how different doses of a water-removing medicine (diuretic) work in adults admitted to hospital with acute heart failure. It will also assess the safety of these treatment approaches. The main questions this study aims to answer are: Does starting with a higher or lower dose of diuretic affect how much sodium and urine the body removes during the first 24 hours? Are there differences in side effects or short-term health outcomes between the treatment approaches? Researchers will compare two treatment approaches that use urine sodium and urine output to guide diuretic treatment with standard care. Participants will receive intravenous diuretic treatment and have their urine sodium, urine output, symptoms, blood tests, and clinical outcomes assessed.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.